מכפיל מחיר להכנסות עתידי Tivic Health Corp (TIVC)

Tivic Health Systems develops unique ClearUP microcurrent devices for sinusitis, protected by patents and FDA approval. The forward P/S of the business on GURU.Markets reflects the revenue valuation trend, where the parameter mark equals 8.40. Clinical trials and Class II certification ensure a high barrier to entry, while a neutral geopolitical backdrop guarantees stable sales in the US.

For Tivic Health Systems (TIVC), whose revenue depends on the marketing of drug-free devices, this metric reflects the market premium for the brand's expansion potential. The ratio of market capitalization to projected sales, represented by the expected P/S ratio, measures the value of future cash flows, allowing the investor to determine whether the company is overvalued relative to its actual pace of niche capture.